The Service Line

Todd Schonherz runs a network of more than 350 cancer providers in 21 states, and a drug wholesaler has agreed to own it. American Oncology Network (AON), the physician-led community oncology group Schonherz leads, agreed October 21 to be acquired by Cencora, the drug distributor that already owns the OneOncology network. The Cencora press release values AON at a $2.4 billion enterprise value: $2.3 billion at closing plus contingent value rights (CVRs) of up to $100 million. Cencora has held about 4 percent since investing in 2020 and expects to pay roughly $1.7 billion in cash to reach 75 percent if certain AON holders roll over 25 percent. The deal needs regulatory clearance and an AON stockholder vote, no closing date has been given, and the next public window is Cencora’s fiscal fourth quarter call on November 4, where it will discuss fiscal 2027. Release language says clinical decisions “will continue to rest with AON’s physicians”; what the filing does not say is how drug purchasing, ancillary revenue, and practice-level autonomy are governed after closing, which is the question every independent practice weighing distributor, private equity, or independence should put to any network it is courting. Confidence: High on deal terms (company release); Medium on how much practice autonomy survives, which depends on documents not yet public.

Reimbursement

Medicare’s first negotiated prices for Part B drugs start January 1, 2028, but the four cancer drugs picked so far are oral, not clinic-infused. The Centers for Medicare and Medicaid Services (CMS) announced the third negotiation cycle January 27 with 15 drugs, the first to include Part B products. The oncology names on the list, Erleada, Kisqali, Lenvima, and Verzenio, are oral therapies covered under Part D, so they do not touch buy-and-bill margin directly. What does matter for infusion practices is how the price will reach them: CMS’s draft effectuation guidance says a manufacturer must either ensure the provider’s acquisition price is no higher than the negotiated price, or refund the difference afterward. Comments closed September 18, with final guidance due this fall. The Community Oncology Alliance (COA) argues that tying the add-on payment to the negotiated price would cut infused-drug add-on revenue 50 to 60 percent starting 2029, a claim from its managing director that is advocacy, not a CMS estimate. Confidence: High on the drug list and process; Low on the COA revenue projection.

Hospital cancer clinics still wait on the final 2027 outpatient rule that would pay 340B-purchased drugs at average sales price minus 33.4 percent. CMS proposed the cut in the Calendar Year 2027 Outpatient Prospective Payment System (OPPS) rule (CMS-1850-P) on July 2, per Targeted Oncology’s coverage of the proposal, which estimates a first-year cut of $4.55 billion in Medicare drug payments, redistributed to non-drug outpatient services under budget neutrality. The final rule is expected later this year. It lands on hospital-owned infusion departments, not on independent practices paid under the physician fee schedule, and every independent-versus-hospital site-of-care comparison changes if the cut survives. Confidence: High that the proposal exists; Medium on the dollar estimate, which is a trade-press calculation.

Enforcement

No new national oncology-specific fraud action surfaced in our scan of the Department of Justice and HHS Office of Inspector General (OIG) pages this week. The most recent chemotherapy-billing case we found, a $1.45 million False Claims Act settlement with a Frederick, Maryland practice and its owner, is dated July 1 and predates this window. We will flag the next one the day it lands.

Who’s Buying

Cencora’s bid for AON, our lead above, is the week’s deal. No second oncology transaction of note surfaced in the window.

Clinical Policy

Three Food and Drug Administration (FDA) cancer approvals landed in ten days, and one of them puts a shot where an infusion used to be. According to the FDA’s oncology approval notifications, Merck’s Keytruda, in both its intravenous form and the subcutaneous Keytruda Qlex, was approved October 16 for previously treated solid tumors with high tumor mutational burden; GSK’s Jemperli was approved October 19, under accelerated approval, for stage II or III mismatch-repair-deficient or MSI-high rectal cancer; and Pfizer’s oral Talzenna with enzalutamide was approved October 26 for metastatic prostate cancer with homologous recombination repair gene mutations. For practices, the subcutaneous option is the operational question: an injection versus an infusion changes chair time and the billing codes in play, so confirm with your Medicare contractor how each is paid before shifting volume. Confidence: High on approvals (FDA); Low on coding treatment, which varies by contractor.

The Operator Metric

About $6.9 million per provider: the rough price tag Cencora is putting on a community oncology network. Divide the $2.4 billion enterprise value by AON’s “more than 350” providers, per the company release, and you get a ceiling near $6.9 million; the figure is our arithmetic, includes up to $100 million in contingent payments, and counts every provider, not only physicians. It is a yardstick, not a multiple: AON’s earnings were not disclosed in the release. Practices fielding offers should ask for the enterprise value, the headcount basis, and the contingent terms in writing. Confidence: Medium (arithmetic from disclosed figures).